CN104271129A - 使用极光激酶抑制剂治疗癌症的方法 - Google Patents

使用极光激酶抑制剂治疗癌症的方法 Download PDF

Info

Publication number
CN104271129A
CN104271129A CN201380015806.1A CN201380015806A CN104271129A CN 104271129 A CN104271129 A CN 104271129A CN 201380015806 A CN201380015806 A CN 201380015806A CN 104271129 A CN104271129 A CN 104271129A
Authority
CN
China
Prior art keywords
cancer
administration
purposes according
paclitaxel
lisai
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380015806.1A
Other languages
English (en)
Chinese (zh)
Inventor
阿里吉特·查克拉瓦蒂
杰弗里·A·埃切迪
罗伯特·W·克莱因菲尔德
卡·N·莱
文·希·徐
卡尔蒂克·文卡塔克里希南
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of CN104271129A publication Critical patent/CN104271129A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380015806.1A 2012-03-20 2013-03-19 使用极光激酶抑制剂治疗癌症的方法 Pending CN104271129A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261613258P 2012-03-20 2012-03-20
US61/613,258 2012-03-20
PCT/US2013/032962 WO2013142491A1 (en) 2012-03-20 2013-03-19 Methods of treating cancer using aurora kinase inhibitors

Publications (1)

Publication Number Publication Date
CN104271129A true CN104271129A (zh) 2015-01-07

Family

ID=48048255

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380015806.1A Pending CN104271129A (zh) 2012-03-20 2013-03-19 使用极光激酶抑制剂治疗癌症的方法

Country Status (24)

Country Link
US (2) US20130303519A1 (https=)
EP (1) EP2827855B1 (https=)
JP (1) JP6373252B2 (https=)
KR (1) KR102128866B1 (https=)
CN (1) CN104271129A (https=)
AU (1) AU2013235275B2 (https=)
CA (1) CA2868024A1 (https=)
EA (1) EA036434B1 (https=)
ES (1) ES2746946T3 (https=)
GE (2) GEP20186900B (https=)
IL (1) IL234686B (https=)
IN (1) IN2014DN08477A (https=)
JO (1) JO3630B1 (https=)
MA (1) MA37438A1 (https=)
MX (1) MX358411B (https=)
MY (1) MY175225A (https=)
NZ (1) NZ700744A (https=)
PH (1) PH12014502109A1 (https=)
SG (2) SG10201607741RA (https=)
TN (1) TN2014000387A1 (https=)
TW (1) TWI649082B (https=)
UA (1) UA117455C2 (https=)
WO (1) WO2013142491A1 (https=)
ZA (1) ZA201407551B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CA2972076A1 (en) * 2014-12-23 2016-06-30 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
JP6786530B2 (ja) * 2015-07-02 2020-11-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラａキナーゼの選択的インヒビターに対する応答のバイオマーカー
CN114681455A (zh) * 2018-08-17 2022-07-01 深圳微芯生物科技股份有限公司 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101547924A (zh) * 2006-11-16 2009-09-30 米伦纽姆医药公司 抑制有丝分裂的化合物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
NZ192803A (en) 1979-02-07 1984-08-24 Hoffmann La Roche Pyrimido-2-benzazepines and pharmaceutical compositions
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5747487A (en) 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
EP0888350A1 (en) 1996-03-08 1999-01-07 Zeneca Limited Azolobenzazepine derivatives as neurologically active agents
EP0946523A1 (en) 1996-12-23 1999-10-06 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
ES2191963T3 (es) 1997-09-29 2003-09-16 Meiji Seika Kaisha Derivados triciclicos de triazolobenzazepina, proceso para la obtencion de los mismos y agentes antialergicos.
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
JP4364637B2 (ja) 2001-08-09 2009-11-18 アクテリオン ファーマシューティカルズ リミテッド 新規なベンゾ縮合へテロ環化合物
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
WO2005076987A2 (en) 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
AU2005243175B2 (en) 2004-05-14 2011-12-01 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase
CN101084214A (zh) 2004-11-17 2007-12-05 迈卡纳治疗股份有限公司 激酶抑制剂
WO2006070198A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
EA200870117A1 (ru) 2005-12-23 2008-12-30 Смитклайн Бичам Корпорейшн Азаиндоловые ингибиторы аурора-киназ
JP2009523784A (ja) 2006-01-16 2009-06-25 ジュビラント・オルガノシス・リミテッド 酸不安定化合物の安定な医薬製剤およびその製造方法
TW200744583A (en) 2006-03-14 2007-12-16 Ranbaxy Lab Ltd Statin stabilizing dosage formulations
DE102006012301A1 (de) 2006-03-15 2007-09-20 Cemag-Anlagenbau-Dessau Gmbh Herstellung von Zementklinker
US7718648B2 (en) 2006-08-09 2010-05-18 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
AU2007314282A1 (en) 2006-10-31 2008-05-08 Achillion Pharmaceuticals, Inc. Elvucitabine pharmaceutical compositions
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
KR101848095B1 (ko) 2008-06-26 2018-04-11 안테리오스, 인코퍼레이티드 경피 운반
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
BR112012020557A8 (pt) * 2010-02-19 2018-01-02 Millennium Pharm Inc formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101547924A (zh) * 2006-11-16 2009-09-30 米伦纽姆医药公司 抑制有丝分裂的化合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HERNAN CAROL,ET AL.: "Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer", 《CANCER CHEMOTHER PHARMACOL》 *
MARK G. MANFREDI,ET AL.: "Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays", 《CLINICAL CANCER RESEARCH》 *
不详: "MLN8237 in Patients With Ovarian,Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer", 《CLINICALTRIAL.GOV》 *

Also Published As

Publication number Publication date
TN2014000387A1 (en) 2015-12-21
US10213436B2 (en) 2019-02-26
UA117455C2 (uk) 2018-08-10
MX2014011324A (es) 2014-12-05
HK1206253A1 (en) 2016-01-08
CA2868024A1 (en) 2013-09-26
IL234686A0 (en) 2014-11-30
JP2015510945A (ja) 2015-04-13
PH12014502109A1 (en) 2014-12-10
US20160193224A1 (en) 2016-07-07
US20130303519A1 (en) 2013-11-14
IL234686B (en) 2020-01-30
TW201343169A (zh) 2013-11-01
GEAP201813599A (en) 2018-06-25
MY175225A (en) 2020-06-16
AU2013235275A1 (en) 2014-10-23
NZ700744A (en) 2016-09-30
ZA201407551B (en) 2019-01-30
KR20140144215A (ko) 2014-12-18
JO3630B1 (ar) 2020-08-27
MA37438A1 (fr) 2016-05-31
ES2746946T3 (es) 2020-03-09
IN2014DN08477A (https=) 2015-05-08
EA201491727A1 (ru) 2015-01-30
WO2013142491A1 (en) 2013-09-26
GEP20186900B (en) 2018-10-10
JP6373252B2 (ja) 2018-08-15
KR102128866B1 (ko) 2020-07-01
AU2013235275B2 (en) 2017-12-07
SG11201405621UA (en) 2014-10-30
SG10201607741RA (en) 2016-11-29
TWI649082B (zh) 2019-02-01
EP2827855A1 (en) 2015-01-28
MX358411B (es) 2018-08-20
EA036434B1 (ru) 2020-11-10
EP2827855B1 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
JP6263468B2 (ja) Ｍｅｋ阻害剤およびオーロラａキナーゼの選択的阻害剤の組み合わせ
IL303376A (en) Tead inhibitors and uses thereof
JP2016535756A (ja) ブロモドメインおよびエクストラターミナル（ｂｅｔ）タンパク質インヒビターを使用するがんのための併用療法
EP3695839A1 (en) Therapeutic agent for solid cancers, which contains axl inhibitor as active ingredient
EP2512469B1 (en) 3-(indolyl)-or 3-(azaindolyl)- 4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarzinoma
TW202023563A (zh) 新穎喹唑啉egfr抑制劑
JP2024537136A (ja) ＫＲＡＳ Ｇ１２Ｄ阻害剤と汎ＥｒｂＢファミリー阻害剤との併用療法
KR20230066401A (ko) 항종양 치료법에서 면역 체크포인트 억제제와 조합된 치아우라닙의 용도
US11878958B2 (en) MEK inhibitors and uses thereof
US10213436B2 (en) Methods of treating cancer using aurora kinase inhibitors
WO2024173761A1 (en) Combinations comprising mek inhibitors for use in the treatment of cancer
CA2782146A1 (en) Small pyrimidine derivatives and methods of use thereof
WO2014002922A1 (ja) 抗癌剤の併用による癌治療方法
US20240208961A1 (en) Eif4e inhibitors and uses thereof
WO2022187849A1 (en) Salinomycin derivatives and uses thereof
HK1206253B (en) Combination of alisertib and paclitaxel for the treatment of cancer
JP2015163591A (ja) 抗癌剤の併用による癌治療方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150107